Proximate spinal disease is a chronic inflammation disease, and many patients, after a period of treatment, are relieved, pain is reduced and joint activity is improved, and they often question whether they can stop using drugs when the condition is eased. The answer is no, for the following reasons: First, the chronic properties of a strong straight spinal column, which is a long-standing disease, although the symptoms can be mitigated by drug treatment, inflammation may persist in the body, but at a relatively low level. It was like an enemy hiding in the dark, temporarily stopping the attack but not being completely eliminated. If the drug stops at this time, it is likely that the inflammation will re-emerge, leading to a relapse, and that previous treatment efforts will be lost. II. Mechanisms for the continued functioning of drugs The treatment of high-relationel spinal disease, especially for the improvement of disease-resistant rheumatism and biological agents, whose effects are not only to mitigate immediate symptoms but, more importantly, to inhibit the pathology of the disease and prevent the further development of joint destruction and spinal malformations. For example, biological agents can accurately target inflammation factors and reduce the erosion of the inflammation response to joints and spinal tissues. This inhibitive effect on the course of the disease will be interrupted and the disease will continue to progress in accordance with its original trends once the drug has stopped. III. Re-emergence of risk and consequences, which tends to be more serious than before, with more severe symptoms and an acceleration of joint damage and spinal malformations. Patients may again experience severe pain, rigidity, increased activity restrictions and even increased disability. Moreover, re-emerging treatment is often more difficult and may require a replacement of the drug or an increase in the dose of the drug, which will undoubtedly impose additional physical burdens, financial stress and psychological distress on the patient. IV. Individualization considerations under the physician ‘ s guidance, of course, cannot be generalized, requiring an individualized assessment under the physician ‘ s professional guidance that combines multiple factors. Doctors take into account the patient ‘ s level of mitigation, whether the inflammation indicator (e.g. blood sank, C reaction protein) is back to normal, changes in the joints and spinal structure as shown by the visual examination, adverse effects of the drug and the overall health status of the patient. In some exceptional cases, for example, after long-term stable relief, patients may try to gradually reduce their doses after careful medical assessment, but this also requires close monitoring and timely adjustment of treatment programmes once repeated indications of the condition are found.
In any case, even if the condition of the direct spinal disease is alleviated, the patient cannot decide to stop using the drug on his or her own, but should maintain close communication with the doctor, following his or her professional advice, and continue to regulate treatment in order to maintain long-term stability, reduce the serious consequences of the recurrence of the disease and guarantee his or her quality of life and physical health.
